Bolt Biotherapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 24, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 24, 2025

BOLT$6.30-2.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Additional · Accumulated Other · Total
Common · Paid-In · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance at December 31, 2022	37,797,902	$—	$467,513	$(919)	$(295,088)	$171,506
Issuance of common stock upon vesting of restricted stock units	58,034	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	254,169	—	247	—	—	247
Issuance of common stock upon exercise of stock options	4,501	—	6	—	—	6
Stock-based compensation	—	—	9,223	—	—	9,223
Unrealized gain on available-for-sale investments	—	—	—	956	—	956
Net loss	—	—	—	—	(69,197)	(69,197)
Balance at December 31, 2023	38,114,606	$—	$476,989	$37	$(364,285)	$112,741
Issuance of common stock upon vesting of restricted stock units	41,713	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	183,378	—	108	—	—	108
Stock-based compensation	—	—	7,407	—	—	7,407
Unrealized gain on available-for-sale investments	—	—	—	60	—	60
Net loss	—	—	—	—	(63,118)	(63,118)
Balance at December 31, 2024	38,339,697	$—	$484,504	$97	$(427,403)	$57,198

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.